Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19417541 | ACACIA NILOTICA BASED HYDROGEL AND METHOD OF MAKING THE SAME | December 2025 | February 2026 | Allow | 2 | 0 | 0 | No | No |
| 19205709 | Vaporized Medicants and Methods of Use | May 2025 | January 2026 | Abandon | 8 | 1 | 0 | No | No |
| 19190359 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME | April 2025 | November 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19187591 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | April 2025 | January 2026 | Allow | 9 | 1 | 1 | No | No |
| 19187241 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | April 2025 | January 2026 | Allow | 9 | 2 | 0 | No | No |
| 19066076 | METHOD FOR PRODUCING A PLANT-BASED EXTRACT COMPOSITION HAVING THE EFFECT OF ENHANCING NUTRITION AND IMMUNITY | February 2025 | June 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19012840 | POLYSACCHARIDE COMPOUND WITH A DEFINED MOLECULAR STRUCTURE THAT CAN ELIMINATE THE TOXIC SIDE EFFECTS OF CHEMOTHERAPY DRUGS | January 2025 | June 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 18980483 | TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING CORONARY MYOCARDIAL BRIDGE AND APPLICATION THEREOF | December 2024 | July 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18961323 | RHODOSORUS MARINUS AND APPLICATION THEREOF IN PREPARING FACIAL MASKS | November 2024 | June 2025 | Allow | 7 | 1 | 1 | No | No |
| 18948016 | PEONY STAMEN-DODDER COMPOSITE, AND ITS PREPARATION METHOD AND APPLICATION | November 2024 | January 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18926515 | GAME ATTRACTANT AND VARMINT REPELLENT COMPOSITIONS AND METHODS | October 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18911447 | MEDICINAL MUSHROOM-BASED TOPICAL COMPOSITION | October 2024 | January 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 18906311 | MEDICAL TREATMENT COMPOSITION, METHOD OF PREPARATION AND TREATMENT METHOD | October 2024 | May 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18844892 | METHOD FOR IMPROVING HEALTH CONDITION OF MAMMAL OR FARM ANIMAL | September 2024 | February 2025 | Allow | 5 | 0 | 0 | No | No |
| 18806195 | SKIN CARE FORMULATIONS | August 2024 | October 2025 | Allow | 14 | 0 | 0 | No | No |
| 18794793 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME | August 2024 | January 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 18764014 | FORMULATIONS AND METHODS FOR SKIN CARE | July 2024 | December 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18760356 | COSMETIC COMPOSITION | July 2024 | February 2026 | Allow | 20 | 1 | 0 | Yes | No |
| 18757390 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | June 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18750691 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | June 2024 | March 2025 | Allow | 9 | 2 | 1 | No | No |
| 18736592 | TRADITIONAL CHINESE MEDICINE COMPOUND FOR PREVENTING AND TREATING AFRICAN SWINE FEVER, AND ITS EFFICIENCY ENHANCEMENT PROCESS AND APPLICATION | June 2024 | October 2024 | Allow | 5 | 0 | 1 | No | No |
| 18736009 | PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDS | June 2024 | January 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18734602 | PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITION | June 2024 | April 2025 | Allow | 10 | 0 | 1 | Yes | No |
| 18734385 | PHOSPHOLIPID COMPOSITIONS FOR DELIVERY OF THERAPEUTIC COMPOUNDS | June 2024 | December 2025 | Allow | 18 | 1 | 0 | No | No |
| 18669211 | Composition for Relieving Sleep Disorder and its Application Method Thereof | May 2024 | December 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18667139 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY | May 2024 | January 2025 | Allow | 8 | 0 | 0 | Yes | No |
| 18709625 | SKIN CARE COMPOSITION | May 2024 | March 2026 | Allow | 22 | 0 | 0 | Yes | No |
| 18661900 | COMPOSITION FOR TREATING BONE LOSS | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18659701 | COMPOSITIONS OF HERBAL FORMULATIONS AND USES THEREOF | May 2024 | May 2025 | Allow | 13 | 0 | 1 | Yes | No |
| 18655974 | STABILIZED COMPOSITIONS COMPRISING CANNABIDIOL | May 2024 | January 2025 | Allow | 9 | 0 | 1 | Yes | No |
| 18654377 | BARRIER GUARD TECHNOLOGY | May 2024 | December 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18639285 | METHODS OF TREATING ENDOMETRIOSIS AND OTHER NONCANCER GYNECOLOGICAL DISORDERS WITH HEMP EXTRACT | April 2024 | May 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18635597 | METHODS OF TREATING OVARIAN CANCER WITH HEMP EXTRACT | April 2024 | June 2025 | Allow | 14 | 1 | 0 | No | No |
| 18621062 | TRADITIONAL CHINESE MEDICINE COMPOUND FOR IMPROVING TESTICULAR DYSFUNCTION, PREPARATION METHOD AND APPLICATION THEREOF | March 2024 | October 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18436468 | FOODS TO PROMOTE BETTER HEALTH AND/OR TO MAINTAIN HOMEOSTAIS AND METHOD OF PRODUCTION THEREOF | February 2024 | December 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18432512 | TIME RELEASE SLEEP AID SYSTEM | February 2024 | May 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18294676 | COMPOSITION BASED ON CROCUS SATIVUS AND CANNABIS SATIVA | February 2024 | December 2025 | Allow | 23 | 0 | 0 | No | No |
| 18431386 | TOPICAL COMPOSITIONS | February 2024 | August 2025 | Abandon | 19 | 2 | 1 | No | No |
| 18429310 | SUSTAINABLE NANOCOMPOSITION FOR TREATMENT OF OSTEOPOROSIS | January 2024 | June 2024 | Allow | 5 | 0 | 1 | No | No |
| 18426754 | BIOFABRICATION OF VAGINAL SUPPORT USING VAGINALLY DERIVED CELLS | January 2024 | December 2025 | Allow | 23 | 0 | 0 | Yes | No |
| 18415902 | HOMEOPATHIC THERAPEUTIC METHOD AND COMPOSITIONS | January 2024 | November 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18410512 | PHYTOCHEMICAL/ NUTRACEUTICAL COMPOSITION FOR MULTIMODAL PROPHYLAXIS AGAINST AND TREATMENT OF VIRAL AND BACTERIAL INFECTION AND INFLAMMATION | January 2024 | May 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18409486 | METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS | January 2024 | February 2026 | Allow | 25 | 1 | 0 | No | No |
| 18407411 | METHOD OF PREVENTING CADMIUM-INDUCED LIVER TOXICITY USING A PLANT PRODUCT DERIVED FROM ACHILLEA MILLEFOLIUM L. | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18576255 | USE OF A VEGETAL EXTRACT FROM SALVIA HAENKEI AS AN ACTIVE AGENT IN THE TREATMENT OF A MUSCULOSKELETAL DISORDER | January 2024 | February 2026 | Allow | 25 | 1 | 0 | No | No |
| 18574200 | COMPOSITIONS FOR THE TREATMENT OF HYPOPIGMENTATION | December 2023 | December 2025 | Allow | 24 | 0 | 0 | No | No |
| 18391194 | METHOD OF TREATING ILLNESS USING LYOPHILIZED CAMEL URINE | December 2023 | September 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18538812 | BOTANICAL FORMULATIONS | December 2023 | December 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18533558 | AQUEOUS WOUND HEALING FORMULATION | December 2023 | June 2025 | Abandon | 18 | 1 | 1 | Yes | No |
| 18531785 | CURCUMIN-BASED COMPOSITIONS & METHODS OF USE THEREOF | December 2023 | September 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18529504 | COMPOSITION FOR TREATING BONE LOSS | December 2023 | April 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18519895 | GYNOSTEMMA PENTAPHYLLUM TEA OR GYNOSTEMMA PENTAPHYLLUM TEA EXTRACT CONTAINING GYPENOSIDE L AND GYPENOSIDE LI AND ANTIOBESITY USE THEREOF | November 2023 | February 2026 | Allow | 27 | 1 | 0 | Yes | No |
| 18519477 | COSMETIC COMPOSITIONS | November 2023 | August 2025 | Abandon | 21 | 2 | 1 | No | No |
| 18518089 | TRADITIONAL CHINESE MEDICINE COMPOSITION FOR PREVENTING AND TREATING DIABETES, TRADITIONAL CHINESE MEDICINE PREPARATION, AND USE THEREOF | November 2023 | October 2025 | Allow | 23 | 0 | 0 | Yes | No |
| 18515789 | CRYSTALLINE FORMS OF PSILACETIN | November 2023 | August 2024 | Allow | 9 | 0 | 1 | Yes | No |
| 18514659 | METHOD FOR PREPARING STABLE LIQUID EMULSION FORMS OF PLANT EXTRACT | November 2023 | December 2025 | Allow | 25 | 2 | 0 | No | No |
| 18512157 | PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18509499 | COMPOSITION FOR PREVENTING OR TREATING GASTRITIS OR PEPTIC ULCER | November 2023 | March 2025 | Allow | 16 | 1 | 0 | No | No |
| 18388854 | THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19 | November 2023 | September 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18388823 | THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19 | November 2023 | September 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18505309 | Topical NSAID Formulation with Improved Skin Absorption | November 2023 | February 2025 | Abandon | 15 | 1 | 1 | No | No |
| 18559889 | USE OF EXTRACELLULAR VESICLES OF RHIZOMA DRYNARIAE IN PREPARATION OF MEDICINE FOR TREATING ORTHOPEDIC DISEASES | November 2023 | April 2025 | Allow | 17 | 1 | 0 | No | No |
| 18388167 | METHOD OF TREATMENT OF CANCERS | November 2023 | April 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18387298 | MEDICAL TREATMENT COMPOSITION, METHOD OF PREPARATION AND TREATMENT METHOD | November 2023 | June 2024 | Allow | 8 | 0 | 1 | Yes | No |
| 18384037 | SKIN PENETRATION ENHANCER FOR ROYAL JELLY | October 2023 | December 2025 | Allow | 26 | 1 | 0 | No | No |
| 18493997 | STABILIZED COMPOSITIONS COMPRISING CANNABIDIOL | October 2023 | April 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18381558 | BETA-ADRENERGIC AGONIST AND MUSCARINIC ANTAGONIST COMPOSITIONS AND METHODS OF USING | October 2023 | April 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18381439 | PHOSPHOLIPID COMPOSITIONS FOR DELIVERY OF THERAPEUTIC COMPOUNDS | October 2023 | April 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18487399 | UVARIA GRANDIFLORA EXTRACT AS A BOTANICAL FUNGICIDE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | October 2023 | October 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18379955 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASE | October 2023 | March 2025 | Allow | 17 | 1 | 0 | No | No |
| 18476580 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | September 2023 | April 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18367577 | Preparation Method of Ginseng Composition with High Ginsenoside Bioavailability | September 2023 | January 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18464967 | Composition for Relieving Sleep Disorder and its Application Method Thereof | September 2023 | April 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18463921 | COSMETIC COMPOSITION CONTAINING EXTRACT OF CYPERUS ROTUNDUS FOR ANTI-INFLAMMATION, SKIN SOOTHING, IRRITATION RELIEF, AND SKIN BARRIER ENHANCEMENT | September 2023 | December 2025 | Allow | 27 | 1 | 0 | Yes | No |
| 18241567 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | September 2023 | April 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18239560 | OIL-BASED INSECTICIDAL AND INSECT REPELLENT COMPOSITIONS | August 2023 | November 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18547601 | PERSONALIZED SKIN CARE COMPOSITIONS | August 2023 | August 2025 | Allow | 24 | 0 | 0 | No | No |
| 18547384 | COSMETIC COMPOSITION COMPRISING BLACK YEAST-DERIVED EXOSOMES | August 2023 | October 2025 | Allow | 25 | 0 | 0 | No | No |
| 18278129 | COSMETIC COMPOSITION FOR DEFORMED NAIL CARE AND PREPARATION METHOD THEREOF | August 2023 | October 2025 | Allow | 26 | 0 | 0 | Yes | No |
| 18236081 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY | August 2023 | May 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18546052 | NOVEL STRAIN AND USE THEREOF | August 2023 | February 2026 | Allow | 31 | 1 | 0 | Yes | No |
| 18364319 | MITOCHONDRIAL TRANSPLANTATION AND USE THEREOF IN OCULAR DISEASES | August 2023 | August 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18275364 | FERMENTED APPLE COMPOSITION | August 2023 | February 2026 | Allow | 30 | 1 | 0 | Yes | No |
| 18228222 | COMPOSITION FOR A FECAL-DERIVED STERILIZED POSTBIOTIC IN ANTI-AGING AND NEUROTHERAPEUTIC APPLICATIONS | July 2023 | June 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18226387 | PROMOTING GROWTH, YIELD, AND SALINITY TOLERANCE OF ACHILLEA FRAGRANTISSIMA | July 2023 | November 2023 | Allow | 4 | 1 | 1 | No | No |
| 18262924 | COMBINATION OF SCUTELLARIA EXTRACTS WITH CITRUS BERGAMIA OR CYNARA CARDUNCULUS EXTRACTS AND FORMULATIONS CONTAINING THEM | July 2023 | February 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18357668 | USE OF ANTRODIA CINNAMOMEA FOR INCREASING ALCOHOL METABOLISM OR/AND HANGOVER | July 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18353992 | HORSERADISH AND CINNAMON MIXED EXTRACT COMPOSITION FOR SUPPRESSION OF AVIAN VIRAL EPIDEMIC DISEASES | July 2023 | December 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18353169 | SAPONIN EXTRACTION | July 2023 | October 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18353172 | SAPONIN EXTRACTION | July 2023 | July 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18222187 | ECM HYDROGEL FOR TREATING ESOPHAGEAL INFLAMMATION | July 2023 | January 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18261332 | A NUTRACEUTICALS FORMULATION WITH AN ENHANCED ORGANOLEPTIC PROPERTIES USED FOR SKIN CARE | July 2023 | January 2026 | Allow | 30 | 0 | 1 | No | No |
| 18221060 | COMPOSITIONS AND METHODS FOR PARENTERAL ADMINISTRATION OF THERAPEUTIC AGENTS | July 2023 | August 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18347535 | BLOOD PLASMA-CONTAINING COMPOSITIONS | July 2023 | June 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18216965 | PROCESSES FOR PRODUCING LOW CHLOROPHYLL, HIGH POLAR LIPID COMPOSITIONS FROM ALGAL OILS AND EXTRACTS | June 2023 | June 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18343765 | FREEZE-DRIED NIPA PALM POWDER AND METHOD OF MANUFACTURING THE SAME | June 2023 | September 2023 | Allow | 3 | 1 | 1 | Yes | No |
| 18038046 | COMPOSITION FOR BLOCKING ULTRAVIOLET RAYS AND FINE DUST, AND PREPARATION METHOD THEREOF | June 2023 | December 2025 | Allow | 31 | 0 | 1 | Yes | No |
| 18214706 | CANNABINOID COMPOSITIONS FOR VIRTUAL AND AUGMENTED REALITY EXPERIENCES | June 2023 | August 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18214062 | IMMUNITY GENERATION | June 2023 | November 2025 | Allow | 29 | 1 | 0 | No | No |
| 18269362 | COSMETIC COMPOSITION COMPRISING FERMENTED GRAPE EXTRACT | June 2023 | January 2026 | Allow | 31 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MI, QIUWEN.
With a 30.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 30.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MI, QIUWEN works in Art Unit 1655 and has examined 1,810 patent applications in our dataset. With an allowance rate of 66.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.
Examiner MI, QIUWEN's allowance rate of 66.3% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MI, QIUWEN receive 1.69 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MI, QIUWEN is 25 months. This places the examiner in the 78% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +52.5% benefit to allowance rate for applications examined by MI, QIUWEN. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 26.7% of applications are subsequently allowed. This success rate is in the 45% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 29.1% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 52.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 46% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 82.7% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 53.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 55.0% are granted (fully or in part). This grant rate is in the 57% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 5.4% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.